ENDRA Life Sciences shares surge 12.77% after-hours as TAEUS® Liver matches MRI-PDFF accuracy, advancing MASLD/MASH trial readiness.

ENDRA Life Sciences Inc. surged 12.77% in after-hours trading following the announcement that its TAEUS® liver device demonstrated performance matching MRI-PDFF standards at key clinical thresholds. The device's accuracy in quantifying liver fat fraction, a critical biomarker for metabolic-associated steatohepatitis (MASH), positions it for use in upcoming MASH trials, according to a Business Wire report. The news aligns with the company’s strategic focus on advancing diagnostic tools for metabolic diseases, reinforcing its market potential. Earlier updates highlighted feasibility study results and a business strategy overhaul, but the recent MRI validation represents a pivotal milestone, likely driving investor optimism.